We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-6.12%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.71B
AUM Growth
-$811M
Cap. Flow
-$127M
Cap. Flow %
-2.7%
Top 10 Hldgs %
32.95%
Holding
146
New
21
Increased
16
Reduced
26
Closed
19

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$114M
2
APLM icon
Apollomics
APLM
+$84.7M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$55.1M
4
ABBV icon
AbbVie
ABBV
+$48.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$37.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.2M
2
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$87.7M
3
UNH icon
UnitedHealth
UNH
+$85.6M
4
EW icon
Edwards Lifesciences
EW
+$48.6M
5
BAX icon
Baxter International
BAX
+$48.4M

Sector Composition

Rank Sector Weight
1 Healthcare 96.83%
2 Miscellaneous 1.94%
3 Industrials 1.1%
4 Consumer Staples 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
76
DELISTED
Ventyx Biosciences
VTYX
$11.8M 0.25%
340,384
-200,600
-37% -$6.94M
ARWR icon
77
Arrowhead Research
ARWR
$10.3B
$11.7M 0.25%
433,651
+316,651
+271% +$9.7M
ACET icon
78
Adicet Bio
ACET
$76.1M
$11.4M 0.24%
520,134
– –
KNTE
79
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$11.2M 0.24%
8,009,729
– –
REGN icon
80
Regeneron Pharmaceuticals
REGN
$80.5B
$11.1M 0.24%
13,500
– –
SGEN
81
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$10.6M 0.23%
+50,000
New +$9.99M
JBIO
82
Jade Biosciences
JBIO
$1.12B
$10.3M 0.22%
21,627
– –
ARQT icon
83
Arcutis Biotherapeutics
ARQT
$2.97B
$10.2M 0.22%
1,914,479
– –
CRVS icon
84
Corvus Pharmaceuticals
CRVS
$1.1B
$10.1M 0.22%
6,943,654
– –
SGEN
85
DELISTED
Seagen Inc. Common Stock
SGEN
$9.04M 0.19%
+42,600
New +$8.51M
GDRX icon
86
GoodRx Holdings
GDRX
$1.2B
$8.98M 0.19%
1,595,000
-193,600
-11% -$1.29M
IVVD icon
87
Invivyd
IVVD
$255M
$8.96M 0.19%
5,270,400
– –
FUSN
88
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$8.12M 0.17%
3,122,770
– –
XFOR icon
89
X4 Pharmaceuticals
XFOR
$357M
$7.78M 0.17%
237,784
– –
GILD icon
90
Gilead Sciences
GILD
$181B
$7.49M 0.16%
100,000
– –
MLTX icon
91
MoonLake Immunotherapeutics
MLTX
$1.04B
$6.67M 0.14%
117,000
– –
PASG icon
92
Passage Bio
PASG
$15.5M
$6.66M 0.14%
506,229
– –
KZR
93
DELISTED
Kezar Life Sciences
KZR
$6.5M 0.14%
546,300
– –
KVUE icon
94
Kenvue
KVUE
$34.2B
$6.27M 0.13%
+312,404
New +$7.23M
NSPR icon
95
InspireMD
NSPR
$36.1M
$6.08M 0.13%
1,860,405
– –
ORIC icon
96
Oric Pharmaceuticals
ORIC
$1.27B
$5.41M 0.11%
893,668
-274,800
-24% -$2.25M
KVUE icon
97
CALL
Kenvue
KVUE
$34.2B
$5.02M 0.11%
+250,000
New +$5.79M
CGEM icon
98
Cullinan Oncology
CGEM
$1.31B
$4.93M 0.1%
544,848
– –
MORF
99
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$4.78M 0.1%
208,500
– –
DXCM icon
100
CALL
DexCom
DXCM
$32.8B
$4.67M 0.1%
+50,000
New +$5.64M
2 3
4
5 6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2023 Portfolio in Review

As of Q3 2023, OrbiMed held 146 positions worth $4.71B, down 15% from $5.52B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed's Q3 2023 filing shows 21 new, 16 increased, 26 reduced and 19 closed positions. Its largest new stake was Merck: 1,055,000 shares worth $109M. The largest sale was Bristol-Myers Squibb, an estimated $95.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Industrials.

  • OrbiMed's largest Q3 2023 buy was Merck: 1,055,000 shares worth $109M.
  • OrbiMed added most to Apollomics in Q3 2023, an estimated $84.7M increase.
  • OrbiMed's biggest Q3 2023 reduction was UnitedHealth, cutting an estimated $85.6M.
  • OrbiMed fully exited Bristol-Myers Squibb in Q3 2023, selling an estimated $95.2M.
  • OrbiMed's ten largest holdings make up 33% of its $4.71B portfolio in Q3 2023.
  • OrbiMed opened 21 new positions and closed 19 in Q3 2023.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $4.71B.

Based on OrbiMed's 13F filing for Q3 2023, filed 14 Nov 2023.